for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Erytech Pharma SA

ERYP.PA

Latest Trade

4.67EUR

Change

-0.12(-2.51%)

Volume

13,660

Today's Range

4.65

 - 

4.80

52 Week Range

4.52

 - 

8.94

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
4.79
Open
4.77
Volume
13,660
3M AVG Volume
0.51
Today's High
4.80
Today's Low
4.65
52 Week High
8.94
52 Week Low
4.52
Shares Out (MIL)
17.94
Market Cap (MIL)
85.92
Forward P/E
-1.53
Dividend (Yield %)
--

Next Event

Erytech Pharma SA Annual Shareholders Meeting

Latest Developments

More

Erytech Pharma H1 Net Loss Widens To 29.3 Million Euros

Erytech Pharma SA Files For Stock Shelf Of Upto $100 Mln

Erytech Announces Immune Modulation Strategic Collaboration With SQZ Biotechnologies

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Erytech Pharma SA

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The Company's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death. The Company's subsidiary is Erytech Pharma, Inc in the USA which legal existence began in April 9, 2014.

Industry

Major Drugs

Contact Info

Batiment Adenine 60 avenue Rockefeller

+33.4.78744438

http://erytech.com/

Executive Leadership

Jean-Paul Kress

Chairman of the Board

Gil Beyen

Chief Executive Officer, Director

Jerome Bailly

Deputy Chief Executive Officer - Chief Pharmacist

Eric Soyer

Chief Financial Officer, Chief Operating Officer

Alexander Scheer

Chief Scientific Officer

Key Stats

1.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-2.740

2017

-2.950

2018

-2.130

2019(E)

-3.130
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

BRIEF-Erytech Pharma H1 Net Loss Widens To 29.3 Million Euros

* REPORTED ON TUESDAY H1 NET LOSS EUR 29.3 MLN VS LOSS EUR 19.0 MLN YEAR AGO

BRIEF-Erytech Announces Immune Modulation Strategic Collaboration With SQZ Biotechnologies

* ERYTECH ANNOUNCED ON MONDAY IT HAS ENTERED INTO AN AGREEMENT WITH SQZ BIOTECHNOLOGIES TO ADVANCE NOVEL RBC-BASED THERAPEUTICS FOR IMMUNE MODULATION

BRIEF-Erytech Pharma Presents New Erymethionase Preclinical Findings

* ERYTECH SAID ON MONDAY IT PRESENTED NEW ERYMETHIONASE PRECLINICAL FINDINGS AT 2019 AACR ANNUAL MEETING

BRIEF- Erytech Pharma FY Total Operating Loss Widens To 43.6 Million Euros

* ANNOUNCED ON MONDAY, ERYTECH PROVIDES BUSINESS UPDATE AND REPORTS FINANCIAL RESULTS FOR FULL YEAR 2018

BRIEF-ERYTECH Partners With New York Blood Center For Red Blood Cell Supply And Research

* NEW YORK BLOOD CENTER (NYBC)TO BECOME LONG-TERM SUPPLIER OF DONOR RED BLOOD CELLS (RBC) TO ERYTECH

BRIEF-Erytech Pharma 9-Month Operating Loss Widens To 34.1 Million Euros

* ANNOUNCED ON MONDAY CASH POSITION OF EUR 146.9 MLN AS OF SEPT 30, 2018, COMPARED WITH EUR 185.5 MLN AS OF DEC 31, 2017

BRIEF-Erytech To Present Results From Phase I Trial Of Eryaspase In All And New Pre Clinical Data At Aacr 2018

* ERYTECH TO PRESENT RESULTS FROM PHASE I TRIAL OF ERYASPASE IN ALL AND NEW PRE-CLINICAL DATA AT AACR 2018 Source text for Eikon: Further company coverage:

BRIEF-Oncodesign Concludes A Partnership With Erytech In Oncology

* ONCODESIGN CONCLUDES A LONG TERM SERVICE-BASED PARTNERSHIP WITH ERYTECH IN ONCOLOGY

BRIEF-Erytech FY Net Loss Widens To 33.5 Million Euros

* REPORTED ON MONDAY FY NET LOSS 33.5 MILLION EUROS, COMPARED TO 21.9 MILLION EUROS IN 2016

BRIEF-Erytech Pharma ‍announces pricing of global offering of 5.4 mln new ordinary shares​

* ANNOUNCES PRICING OF GLOBAL OFFERING TO SPECIFIED CATEGORIES OF INVESTORS OF AGGREGATE OF 5.4 MILLION NEW ORDINARY SHARES

BRIEF-Erytech Pharma announces trading suspension of its ordinary shares on Euronext paris​

* ERYTECH ANNOUNCES TRADING SUSPENSION OF ITS ORDINARY SHARES ON EURONEXT PARIS

BRIEF-Erytech Pharma 9M net loss widens to 20.8 million euros

* ANNOUNCED ON MONDAY 9M NET LOSS OF EUR 20.8 MLN VS PROFIT OF EUR 16.1 MLN YEAR AGO

BRIEF-Erytech Pharma sees U.S. IPO of up to 4.26 mln ordinary shares in form of ADSs

* Erytech Pharma SA sees U.S. IPO of up to 4.26 million ordinary shares in form of American Depositary Shares, or ADSs - sec filing

BRIEF-Erytech Pharma ‍announces resubmission of european marketing authorization application for GRASPA

* ANNOUNCES RESUBMISSION OF EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR GRASPA IN ACUTE LYMPHOBLASTIC LEUKEMIA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Erytech Pharma files for U.S. IPO of up to $100 mln of ADSS

* Erytech Pharma Sa files for U.S. IPO of up to $100 million of ADSS - SEC filing

BRIEF-Erytech Pharma H1 net loss widens to 14.0 million euros

* ERYTECH REPORTS FIRST HALF 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Erytech Pharma's complete results demonstrate statistically improvement in overall survival and progression-free survival

* COMPLETE DATA DEMONSTRATE A STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL

BRIEF-Erytech announces collaboration with Queen’s University

* ERYTECH ANNOUNCES COLLABORATION WITH QUEEN’S UNIVERSITY TO ADVANCE ITS PRODUCT CANDIDATE FOR RARE METABOLIC DISORDERS

BRIEF-Erytech Pharma cash balance of 30.5 million euros as of March 31, 2017

* REPORTED POSITIVE PHASE 2B DATA FROM FRENCH MULTI-CENTER STUDY OF ERYASPASE FOR TREATMENT OF METASTATIC PANCREATIC CANCER

BRIEF-Erytech to raise 70.5 million euros in private placement

* Erytech to raise 70.5 million euros ($75.19 million)in a private placement to U.S. aeuropean investors

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up